

# **Prenatal multiple micronutrient-fortified balanced energy-protein supplementation and newborn telomere length and mitochondrial DNA content: a randomized controlled efficacy trial in rural Burkina Faso**

**Short title:** BEP supplementation, telomere length, and mitochondrial DNA

## **Authors:**

Giles T. Hanley-Cook,<sup>1\*</sup> Yuri Bastos-Moreira,<sup>1,2\*</sup> Dries S. Martens,<sup>3</sup> Trenton Dailey-Chwalibóg,<sup>1</sup> Laeticia Celine Toe,<sup>1,4</sup> Brenda de Kok,<sup>1</sup> Lionel Ouédraogo,<sup>1,5</sup> Alemayehu Argaw,<sup>1</sup> Kokeb Tesfamariam,<sup>1,2</sup> Patrick Kolsteren,<sup>1</sup> Lieven Huybregts,<sup>1,6</sup> Tim S. Nawrot,<sup>3,7</sup> Sarah De Saeger<sup>2,8</sup>, Marthe De Boevre,<sup>2</sup> Carl Lachat<sup>1</sup>

\*These authors contributed equally to the work.

## **Affiliations:**

<sup>1</sup> Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium

<sup>2</sup>Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH<sup>®</sup> Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

<sup>3</sup> Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium

<sup>4</sup> Unité Nutrition et Maladies Métaboliques, Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso

<sup>5</sup> Centre Muraz, Bobo-Dioulasso, Burkina Faso

<sup>6</sup> Nutrition, Diets, and Health Unit, Department of Food and Nutrition Policy, International Food Policy Research Institute (IFPRI), Washington, DC, United States of America

<sup>7</sup>Department of Public Health & Primary Care, University of Leuven, Leuven, Belgium

<sup>8</sup>Department of Biotechnology and Food Technology, Faculty of Science, University of Johannesburg, Doornfontein Campus, Gauteng, South Africa

**Short title:** BEP, telomere length, and mitochondrial DNA

**Corresponding author**

Carl Lachat; Coupure Links 653, 9000 Ghent, Belgium;

[Carl.Lachat@UGent.be](mailto:Carl.Lachat@UGent.be); +32 486 9 264 9377

Giles Hanley-Cook; Coupure Links 653, 9000 Ghent, Belgium;

[Giles.HanleyCook@UGent.be](mailto:Giles.HanleyCook@UGent.be); +32 9 264 9377

Yuri Bastos-Moreira ; Coupure Links 653, 9000 Ghent, Belgium;

[Yuri.BastosMoreira@UGent.be](mailto:Yuri.BastosMoreira@UGent.be); +32 467 68 9198

1 **Abstract**

2 **Background:** Evidence regarding the effectiveness of prenatal nutritional supplements has  
3 mainly considered anthropometric pregnancy outcomes. The effect on markers of health and  
4 disease, such as offspring telomere length (TL) and mitochondrial DNA content (mtDNAc) is  
5 unknown.

6 **Objectives:** We assessed the efficacy of maternal multiple micronutrient (MMN)-fortified  
7 balanced-energy protein (BEP) and iron-folic acid (IFA) supplementation on newborn TL as a  
8 secondary outcome and mtDNAc as a non-declared outcome.

9 **Design:** We conducted a randomized controlled trial in rural Burkina Faso, among pregnant  
10 females (15-40 years old) enrolled at <21 weeks of gestation. Mothers received either MMN-  
11 fortified BEP and IFA (intervention) or IFA only (control) throughout pregnancy. Whole  
12 arterial blood samples were collected from the umbilical cord of 104 control and 90  
13 intervention group infants, respectively. Average relative TL and mtDNAc were measured  
14 using quantitative polymerase chain reaction. Linear regression models were fitted to assess  
15 TL and mtDNAc differences across trial arms.

16 **Results:** We found that a combined daily MMN-fortified BEP supplement and IFA tablet did  
17 not affect newborn TL [ $\beta = -0.010$  (95% CI: -0.057, 0.036);  $P = 0.662$ ] or mtDNAc [ $\beta = 0.065$   
18 (95% CI: -0.203, 0.073);  $P = 0.354$ ], as compared to an IFA tablet alone. These findings were  
19 confirmed ( $P > 0.05$ ) by adjusting the regression models for potential prognostic factors of  
20 study outcomes at enrollment. Exploratory analyses indicated higher, but non-significantly  
21 different mtDNAc among children born either small-for-gestational age, low birthweight, or  
22 preterm.

23 **Conclusions:** Newborns from mothers who received daily nutritional supplements across  
24 gestation did not have different relative TL or mtDNAc.

25 **Keywords:** balanced-energy protein, Burkina Faso, iron-folic acid, mitochondrial DNA,  
26 multiple micronutrients, randomized controlled trial, telomere length

## 27 **Introduction**

28 Prenatal multiple micronutrient (MMN) and balanced-energy protein (BEP) supplementation  
29 are strategies proposed to tackle maternal nutrient deficiencies and consequently reduce risks  
30 of small-for-gestational age (SGA), low birth weight (LBW), stillbirth, and increased birth  
31 weight, among malnourished females (1). Evaluating the effects of prenatal nutritional  
32 interventions on newborn biomarkers, rather than only on anthropometric outcomes (e.g.,  
33 SGA, LBW), might provide more granular insights into nutritional impacts *in utero*.  
34 Moreover, such assessments likely further advance the mechanistic understanding of the  
35 developmental origins of health and disease phenomenon and subsequently help predict long-  
36 term risks, including disease vulnerability. Two potential biomarkers of interest are telomere  
37 length (TL) (2) and mitochondrial DNA content (mtDNAc) at birth (3).

38 The developmental origins of health and disease hypothesizes that harmful intrauterine  
39 exposures, including suboptimal maternal nutrition (4), might program the fetus to develop  
40 chronic diseases and overweight and obesity, when in a more favorable nutritional  
41 environments later in life (5). The presumed cellular adaptations are thought to involve  
42 epigenetic modifications , which amend their life-long expression without altering  
43 deoxyribonucleic acid (DNA) sequences (6–8).

44 Telomeres are non-coding, double-stranded, tandem repeats [5'-(TTAGGG)<sub>n</sub>-3'] of  
45 nucleotide sequences located at the tip of chromosomes. Telomeres maintain genome  
46 integrity, by protecting DNA coding sequences from degradation and preventing the aberrant  
47 fusion of chromosomes (9). In somatic cells, telomeres shorten after each cell division (i.e.,  
48 50-100 base pairs), due to incomplete replication of DNA molecules and maintenance  
49 mechanisms that are not able to prevent telomere attrition (10). TL shortening results in DNA  
50 damage, interruption of cellular function, chromosomal fusion, and cell senescence. TL at  
51 birth is a biological marker that may shape the human aging-phenotype later in life (11).

52 Shorter TL has been consistently associated with higher mortality (12) and chronic disease  
53 rates, such as cardiovascular disease (13) and type II diabetes (14).

54 Mitochondria are known for their role in energy production by aerobic respiration in the form  
55 of adenosine triphosphate (ATP) (15). Predominantly maternally inherited, circular, double-  
56 stranded mtDNA is in theory more prone to damage due to oxidative stress-induced damage,  
57 caused by its proximity to the sites of oxidative phosphorylation (e.g., reactive oxygen  
58 species), and lack of protection from histones present in nuclear DNA (16,17). In pregnancies  
59 ending in fetal growth restriction or LBW, mtDNA has been observed to be elevated in  
60 maternal blood (18) and placental samples (19), indicating mitochondrial dysfunction. In the  
61 neonatal period and during infancy, mitochondrial dysfunction has been related to a myriad of  
62 clinical symptoms, including cerebral ataxia, poor weight gain, and heart arrhythmia (20,21),  
63 and the pathogenesis of chronic diseases in adulthood, including Alzheimer's and cancer (22).

64 To date, two experimental studies have assessed the effectiveness of MMN-fortified  
65 supplements on children's TL. In Ghana, prenatal supplementation had no impact on TL at 4-  
66 6 years of age as compared to iron-folic acid (IFA) (23), while in Bangladesh combining  
67 improved water, sanitation, and hygiene practices with child micronutrient fortified lipid-  
68 based nutrient supplementation (6-24 month of age) led to shorter TLs at 1 year, indicating  
69 increased telomere attrition, as compared to the control group (24). Furthermore, prenatal  $\omega$ -3  
70 supplementation did not increase offspring TL in Australia (25). Likewise, no beneficial  
71 effects were observed on TL in adults during a 5-year Mediterranean diet or a 12-week  
72 almond-enriched dietary interventions in Spain (26) and Australia (27), respectively.  
73 However, adults receiving a daily combination of vitamin supplements for 6 to 12 months had  
74 longer TLs in Greece, as compared to the control group (28). In addition, one trial assessed  
75 the impact of prenatal MMN supplementation on females' mtDNA in maternal venous blood

76 prior to delivery in Indonesia, and reported lower post-supplementation mtDNA compared to  
77 IFA, indicating improved mitochondrial efficiency (29).

78 The MISAME-III randomized controlled trial (RCT) assessed the efficacy of a prenatal  
79 MMN-fortified BEP supplement and IFA tablet among pregnant females in rural Burkina  
80 Faso, as compared to IFA alone on newborn relative TL and mtDNAc (30). Newborn TL was  
81 registered as a secondary outcome but mtDNAc was as non-declared outcome that was  
82 considered relevant for the trial during the analysis of the samples. The findings from these  
83 analyses will help characterize the physiological impact of MMN-fortified BEP  
84 supplementation, given the previously reported modest effects on the primary outcomes at  
85 birth and linear growth of infants at 6 months (31).

## 86 **Methods**

87 Our research was reported using the Consolidated Standards of Reporting Trials (CONSORT)  
88 2010 checklist (32) and Minimum Information for Publication of Quantitative Real-Time  
89 PCR Experiments (MIQE) guidelines (33).

## 90 **Study setting**

91 The prenatal phase of the MISAME-III study was took place between the first enrolment on  
92 30 October 2019 and the last delivery on 7 August 2021 in the catchment areas of six rural  
93 health centers of the health district of Houndé, Tuy Province, in the Hauts-Bassins region of  
94 Burkina Faso (34,35). Malaria transmission is perennial, with seasonal variations. The usual  
95 diet during pregnancy is non-diverse (36), predominantly maize-based with a complement of  
96 leafy vegetables (37), and consequently dietary micronutrient intakes are inadequate to cover  
97 the Estimated Average Requirements (EARs) (38). Moreover, among a subsample of  
98 MISAME-III females the mean energy intake of the base diet (i.e., excluding supplements)  
99 was estimated to be ~1,940 kcal in both trial arms at the end of the pre-harvest season (39).

## 100 **Study design, participants, and enrolment procedures**

101 The MISAME-III protocol containing all procedures was published previously (30). The  
102 study was a community-based, non-blinded individually randomized  $2 \times 2$  factorial RCT,  
103 with directly observed daily supplement intake. The RCT specified one primary prenatal  
104 outcome: SGA [ $<10^{\text{th}}$  percentile of the International Fetal and Newborn Growth Consortium  
105 for the 21st Century (INTERGROWTH-21<sup>st</sup>) new-born size standards (40)]. Secondary and  
106 exploratory biological outcomes of the prenatal BEP intervention were relative newborn TL  
107 and mtDNAc at birth, respectively.



108 Females aged between 15 and 40 years and living in the study villages were identified by way  
109 of a census in the study area ( $n = 10,165$ ). A network of 142 locally trained community  
110 support staff visited all eligible females at their homes every five weeks to identify pregnancy  
111 early, by screening for self-reported amenorrhea. Females suspected to be pregnant were  
112 referred to the health center for a urine pregnancy test. Once gestation was preliminarily  
113 confirmed, the MISAME-III study purpose and procedures were explained in the local  
114 language: Bwamu, Mooré, or Dioula. Prior to randomization, we excluded females who  
115 intended to leave the study area during their pregnancy, planned to deliver outside the study  
116 area, or mothers who had a peanut allergy since the BEP supplement is an energy-dense  
117 peanut paste fortified with MMNs (31).

118 After written informed consent was obtained, females (pregnancy not yet confirmed by an  
119 ultrasound) were randomly assigned to receive either a daily MMN-fortified BEP supplement  
120 and IFA tablet (intervention group) or a daily IFA tablet alone (control group) during  
121 pregnancy.

122 The stratified randomization scheme per health center was generated by an external research  
123 analyst before the start of the study with Stata 15.1 (StataCorp, College Station, TX), in  
124 permuted blocks of eight (4 control, 4 intervention). The allocation was coded with the letter  
125 A for the prenatal control arm and the letter B for the prenatal intervention arm.

126 Randomization codes were concealed in sequentially numbered sealed opaque envelopes by  
127 project employees, who were not in direct contact with enrolled women. The project  
128 midwives who enrolled participants, assigned women to a trial arm by drawing a sealed  
129 envelope containing the A/B letter code. MISAME-III enrolment ran from 30 October 2019 to  
130 12 December 2020. Within 14 days of enrolment, a female's pregnancy was definitively  
131 confirmed by an ultrasound. Gestational age (GA) was estimated by measuring crown-rump  
132 length (7-13 weeks) or by calculating the mean of three to four measurements: bi-parietal

133 diameter, head circumference, abdominal circumference, and femur length (12-26 weeks)

134 (23). Post-randomization, we excluded non-pregnant women, mothers with a GA  $\geq$ 21

135 completed weeks, and multi-fetal pregnancies (i.e., not meeting the *a priori* defined study

136 inclusion criteria) (41).

137 Trained village-based project workers visited 10-25 pregnant females per day to ensure the

138 directly observed intake of MMN-fortified BEP supplements and IFA tablets. When females

139 had a short and scheduled absence from home, MMN-fortified BEP and IFA were given to

140 the pregnant females in advance (thus, counted as non-observed intakes for the respective

141 days). The home visitors also encouraged pregnant females to attend at least four scheduled

142 antenatal care (ANC) visits approximately every seven weeks. All serious adverse events

143 (e.g., miscarriage and stillbirth) were recorded on a case-by-case basis, and verbal autopsies

144 were performed by the MISAME-III physician for maternal or infant deaths that occurred

145 outside a health center.

146 Newborn arterial umbilical cord blood samples were collected from April 2021 onwards, at

147 which time 304 females (164 control, 140 intervention) were still actively enrolled in the

148 MISAME-III trial.

## 149 **Study supplements**

150 In 2016, the Bill & Melinda Gates Foundation convened an expert group to recommend the

151 optimal nutritional composition of the BEP supplement (42). In a formative study, the most

152 preferred and suitable MMN-fortified BEP supplement was selected for administration in the

153 MISAME-III efficacy trial (43,44). The BEP supplement is a lipid-based nutrient supplement

154 in the form of an energy-dense peanut paste fortified with MMN. The BEP is ready-to-

155 consume, does not require a cold chain, and has a long shelf life. On average, the 72g MMN-

156 fortified BEP provided 393 kcal and consisted of 36%, 20%, and 32% energy from lipids,

157 protein, and carbohydrates, respectively. Furthermore, the MMN content alone covered at  
158 least the daily EARs of micronutrients for pregnant females, except for calcium, phosphorous,  
159 and magnesium (45). The complete nutritional composition of the MMN-fortified BEP is  
160 provided in **Supplemental Table 1**.

161 Females in the intervention group received a daily MMN-fortified BEP supplement and an  
162 IFA tablet [65 mg iron (form:  $\text{FeH}_2\text{O}_5\text{S}$ ) and 400  $\mu\text{g}$  folic acid (form:  $\text{C}_{19}\text{H}_{19}\text{N}_7\text{O}_6$ ; Tolerable  
163 Upper Intake Level from fortified food or supplements, not including folate from food: 1000  
164  $\mu\text{g}/\text{d}$  (46)], whereas females in the control group received a daily IFA tablet only (Sidhaant  
165 Life Sciences, Delhi, India), in accordance with Burkina Faso's national health protocol (i.e.,  
166 standard of care). Following Burkinabe guidelines, all enrolled females received malaria  
167 prophylaxis (three oral doses of sulfadoxine-pyrimethamine) at the relevant ANC visits.

#### 168 **Data collection and measures**

169 At enrolment (i.e., first ANC visit), we measured maternal height, weight, mid-upper arm  
170 circumference (MUAC) in duplicate, and hemoglobin (Hb) concentration. In addition, a  
171 comprehensive socio-economic and demographic questionnaire was administered at baseline  
172 (30).

173 Maternal height was measured to the nearest 1 cm using a ShorrBoard® Infant/Child/Adult  
174 (Weigh and Measure, Olney, MD) and weight to the nearest 100 g with a Seca 876 scale  
175 (Seca, Hanover, MD); and the accuracy of the scales was verified weekly. Maternal MUAC  
176 was measured to the nearest 1 mm using a Seca 212 measuring tape (Seca, Hanover, MD).  
177 Pregnant females' Hb concentration was measured by spectrophotometry with a HemoCue®  
178 Hb 201+ (HemoCue, Ängelholm, Sweden); and a weekly calibration check was made with  
179 the use of a HemoCue Control Cuvette. The study's physician performed trans-abdominal  
180 ultrasound fetal biometry within two weeks of enrollment. Pregnancy was confirmed and GA

181 was estimated using a portable diagnostic imaging and full-color, flow-mapping SonoSite M-  
182 Turbo (FUJIFILM SonoSite Inc., Bothell, WA). Concurrently, maternal subscapular and  
183 tricipital skinfold measurements were taken in triplicate using a Harpenden caliper.

184 At birth, anthropometry of all newborns was assessed in duplicate within 12 hours by study  
185 midwives at the health center. Birth weight was measured to the nearest 10 g with a Seca 384  
186 scale (Seca, Hanover, MD). If there was a large discrepancy between weight measures (i.e.,  
187 >200 g), a third measurement was taken. The average of the two closest measures were used  
188 for analyses (i.e., SGA and LBW). The accuracy and precision of anthropometric  
189 measurements were established regularly through standardization sessions organized by an  
190 expert in anthropometry (47).

191 The arterial umbilical cord blood collection procedure was described in detail previously (48).  
192 Within 30 minutes post-partum, arterial umbilical cord blood ( $n = 195$ ) was sampled, by an  
193 arterial puncture, into 4 mL BD Vacutainer® plastic whole blood tubes with spray-coated K2  
194 potassium salt of ethylene diamine tetra acetic acid (EDTA) (BD, Franklin Lakes, NJ), which  
195 was gently inverted (at least 10 times) for thorough mixing of blood with the anticoagulant.  
196 Blood samples were aliquoted, using micropipettes (Thermo Fisher Scientific, Life  
197 Technologies, Europe), into sterile cryotubes (Biosigma, Cona VE, Italy) and flash frozen in  
198 12 L liquid nitrogen storage vessels (Cryopal, Air Liquide, Paris, France). Umbilical cord  
199 blood samples collected after working hours (i.e., after 18:00 until 06:00) were gently  
200 inverted to mix and placed at 0-4 °C, before being aliquoted and flash frozen. Once liquid  
201 nitrogen storage vessels were full, samples were transferred to a -80 °C freezer at the Institut  
202 de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso. Samples were shipped  
203 in dry ice to the allocated biobank of the MISAME-III study in the Centre of Excellence in  
204 Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University  
205 and stored at -80 °C. For DNA extraction, samples were transferred in dry ice to the Centre

206 for Environmental Sciences, Hasselt University and stored at -80°C. All blood samples were  
207 subjected to one freeze-thaw cycle.

208 MISAME-III field data were collected using SurveySolutions v.21.5 on tablets by the project  
209 physician and midwives, which were transferred to a central Ghent University server weekly.  
210 Questionnaire assignments were sent once a week to the field team including preloaded data  
211 collected at a previous ANC visit to lower the amount of incorrect data. Furthermore, we  
212 programmed generic validation codes to avoid the entry of implausible values and to improve  
213 the quality of data collection in the field. Additionally, bi-weekly data quality checks and  
214 missing or inconsistent data were sent back to the field for revision. The quality of ultrasound  
215 images and estimation of GA were checked for >10% of the examinations regularly by an  
216 external gynecologist, using a quality checklist and scoring sheet. The trained project workers  
217 collected daily data on MMN-fortified BEP and IFA compliance in both prenatal study arms  
218 by smartphone-assisted personal interviewing programmed in CSPro v.7.3.1. Six supervisors  
219 performed monthly Lot Quality Assurance Sampling schemes of each home visitor's work on  
220 a random day (49).

## 221 **Relative telomere length and mitochondrial DNA content**

222 DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen, Inc., Venlo, the  
223 Netherlands). DNA quantity and purity were assessed by a Nanodrop 1000 spectrophotometer  
224 (Isogen, Life Science, Belgium). DNA was considered pure when the A260/280 was greater  
225 than 1.80 and A260/230 greater than 2.0. All isolated DNA was stored at -25 °C at the  
226 molecular biology laboratory of the Centre for Environmental Sciences, Hasselt University.

227 DNA integrity was assessed by agarose gel-electrophoresis. To ensure a uniform DNA input  
228 of 5 ng for each quantitative polymerase chain reaction (qPCR), samples were diluted and  
229 checked using the Qubit 1X dsDNA HS Assay Kit (Thermo Fisher Scientific, Life  
230 Technologies, Europe) (50).

231 Relative TL and mtDNAc were measured using a real-time qPCR method in which telomere  
232 specific amplification is performed using primers described by Cawthon (51), as well as  
233 mtDNA amplification using primers (i.e., targeting the ND1 mitochondrial gene) described by  
234 Janssen *et al.* (52). A single-copy gene (S), in this case, human beta globin specific primers  
235 were used (53). The telomere-specific qPCR reaction mixture contained 1x KAPA SYBR Fast  
236 PCR master mix (Merck KGaA, Darmstadt, Germany), 2 mM dithiothreitol (DTT), 100 nM  
237 telg primer (5'-ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT-3') and  
238 100 nM telc primer (5'-TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA-  
239 3'). The following cycling conditions were applied: 1 cycle at 95 °C for 3 minutes, 2 cycles at  
240 94 °C for 3 seconds, 49 °C for 15 seconds, 30 cycles at 94 °C for 3 seconds, 62 °C for 5  
241 seconds, and 74 °C for 10 seconds. The mtDNA (MT-ND1) reaction mixture contained 1x  
242 KAPA SYBR Fast PCR master mix, 450 nM forward (5'- ATGGCCAACCTCCTACTCCT-  
243 3'), 450nM reverse (5'- CTACAACGTTGGGGCCTTT-3') primer, and 5 ng DNA. The  
244 cycling conditions were: 1 cycle at 95 °C for 3 minutes, 40 cycles at 95 °C for 3 seconds, and

245 58 °C for 15 seconds. The single-copy gene qPCR mixture contained 1x KAPA SYBR Fast  
246 PCR master mix, 450 nM HBG1 primer (5'-GCTTCTGACACAACACTGTGTTCACTAGC-3'),  
247 and 450 nM HBG2 primer (5'-CACCAACTTCATCCACGTTTACC-3'). Cycling conditions  
248 were similar for mtDNA. All measurements were performed in triplicate on a QS5 Fast Real-  
249 Time PCR System (Applied Biosystems, Waltham, MA) in a 384-well format (54).

250 After each qPCR a melting curve analysis was performed. On each run, PCR efficiency was  
251 evaluated using two standard 6-point serial diluted standard curves (108% for TL, 120% for  
252 MT-ND1, and 96% for SCG with an  $R^2 > 0.994$  for all standard curves). Nine inter-run  
253 calibrators (IRCs) were run to account for inter-run variability. Relative leukocyte TL and  
254 mtDNAc were calculated using the qBase software (Biogazelle, Zwijnaarde, Belgium). In  
255 qBase, TL and mtDNA are calculated as a calibrated normalized relative quantity (CNRQ)  
256 (55). The latter is achieved by first calculating the relative quantity (RQ) based on the delta-  
257 Cq method for telomere copy number (T), mitochondrial gene copy number (M), and S  
258 obtained Cq values, using target specific amplification efficiencies. Since the choice of a  
259 calibrator sample (i.e., sample to which subsequent normalization is performed, delta-delta-  
260 Cq) strongly influences the error on the final RQs (due to measurement errors on the  
261 calibrator sample), normalization is performed to the arithmetic mean quantification values  
262 for all analyzed samples, which results in the normalized relative quantity (NRQ). Finally, as  
263 samples are measured over multiple qPCR plates, 9 IRCs are used to calculate an additional  
264 correction factor to eliminate run-to-run differences, resulting into the final T/S and M/S  
265 ratios (i.e., CNRQ). Mathematical calculation formulas to obtain RQ, NRQ, and CNRQs are  
266 provided by Hellemans *et al.* (55).

267 The inter- and intra-assay repeatability were assessed by calculating the intraclass correlation  
268 coefficient (ICC) with 95% CI of triplicate measures for the IRCs (inter-assay) and all T/S  
269 ratios and M/S ratios (intra-assay) the ICC R-code provided by the Telomere Research

270 Network (56). The inter-assay ICC for TL was 0.97 (95% CI: 0.88, 0.99;  $P < 0.0001$ ) and 0.93  
271 (95% CI: 0.74, 0.98;  $P < 0.0001$ ) for mtDNAc. The intra-assay repeatability for TL and  
272 mtDNAc were 0.89 (95% CI: 0.86, 0.91;  $P < 0.0001$ ) and 0.96 (95% CI: 0.95, 0.97;  
273  $P < 0.0001$ ).



274 **Statistical analysis**

275 For consistency and comparability of study findings, the present complete cases analyses  
276 followed the analytical procedures used to assess the efficacy of the prenatal MMN-fortified  
277 BEP intervention on birth (31) and maternal outcomes (57). The MISAME-III statistical  
278 analysis plan was validated on October 24, 2019 and published online on November 3, 2020  
279 on the study's website: [https://www.misame3.ugent.be/resource-files/MISAME-](https://www.misame3.ugent.be/resource-files/MISAME-III_SAP_v1_102019.pdf)  
280 [III SAP v1 102019.pdf](https://www.misame3.ugent.be/resource-files/MISAME-III_SAP_v1_102019.pdf).

281 In line with the analysis of primary outcomes, we restricted our analyses to singleton  
282 pregnancies. Descriptive data are presented as frequencies (%), means  $\pm$  SDs, or medians  
283 [interquartile ranges (IQRs)]. Unadjusted and adjusted group differences were estimated by  
284 fitting linear regression models for the continuous T/S and M/S outcomes, to estimate the  
285 mean group difference. The assumptions of normality were checked by visual inspection of  
286 the standardized normal probability and quantile-quantile plots of the residuals  
287 (**Supplemental Figure 1, Supplemental Figure 2**). All models were adjusted for health  
288 center, randomization block, and qPCR plate as a fixed effects to account for clustering by the  
289 study design. Adjusted models additionally contained a set of potential baseline prognostic  
290 factors of newborn TL and mtDNAC, including wealth index (0-10 points), maternal age  
291 (years), primiparity, GA (weeks), height (cm), MUAC (mm), body mass index (kg/m<sup>2</sup>), and  
292 Hb level (g/dL) at study enrolment. We did not adjust for any other socio-demographic  
293 variables, due to balanced baseline characteristics across prenatal study groups (i.e.,  $<|2.5|$   
294 percentage points difference). As sensitivity analyses, we additionally included the age (years)  
295 of the household head at enrolment as a proxy for the father's age (58) and the time (minutes)  
296 between umbilical cord blood collection and storage in the liquid nitrogen vessel.

297 We followed an approach used by Katz *et al.* (59), Roberfroid *et al.* (60), and de Kok *et al.*  
298 (31) to explore whether the treatment effects on T/S and M/S ratios were constant over

299 percentiles of newborns' T/S and M/S ratios distributions, respectively. In this method,  
300 differences (and CIs) in biological outcomes between intervention and control groups were  
301 estimated as nonlinear smooth functions of every aggregated 4<sup>th</sup> percentile of newborn TL or  
302 mtDNAc distributions, with knots set at the 20<sup>th</sup>, 40<sup>th</sup>, 60<sup>th</sup>, and 80<sup>th</sup> percentiles. Furthermore,  
303 we conducted stratified analyses by child sex, to evaluate any potential effect modification.  
304 Lastly, as an exploratory analysis, we assessed TL and mtDNAc across adverse birth  
305 phenotypes (i.e., SGA, LBW, or preterm).

306 Statistical significance was set at  $P < 0.05$  for all two-sided tests, except for exploratory  
307 interactions for which  $P < 0.10$  was used. All analyses were conducted with Stata 16.1  
308 (StataCorp, College Station, TX).

309 **Results**

310 Between October 2019 and December 2020, 2,016 females were assessed for eligibility, of  
311 whom 1,897 were randomized (960 control, 937 intervention) and 119 excluded for not  
312 meeting the MISAME-III's inclusion criteria. In April 2021, 304 females (164 control, 140  
313 intervention) were still participating in the efficacy trial. Among the 195 pregnant females,  
314 from whom umbilical cord blood samples were collected between April 2021 and August  
315 2021 (105 control, 90 intervention), one female was excluded from the control group post-  
316 randomization, due to her GA at inclusion being  $\geq 21$  completed weeks (i.e., confirmed by an  
317 ultrasound, after an initial urine pregnancy test). Lastly, two (0 control, 2 intervention) and  
318 three women (1 control, 2 intervention) were removed from T/S and M/S ratio analyses, due  
319 to insufficient DNA (**Figure 1**). The median (IQR) time between umbilical cord blood  
320 collection and storage in the liquid nitrogen vessel was 0 (0, 491) minutes in the control group  
321 and 0 (0, 550) minutes in the intervention group.

322 The baseline characteristics of eligible pregnant females (104 control, 90 intervention) are  
323 presented in **Table 1**. In response to a reviewer comment regarding potential baseline  
324 imbalances, and in recognition that baseline statistical tests in randomized controlled trials are  
325 not fundamentally incorrect, *P*-values are provided in **Supplemental Table 2**. The prenatal  
326 trial arms were balanced regarding household, maternal, and pregnancy characteristics. At  
327 baseline, 70.1% of households were food insecure, 58.1% and 62.9% of households had  
328 improved water sources and sanitation, respectively, 46.4% of pregnant females completed  
329 primary education, 6.19% were underweight, 26.3% were anemic, and their mean  $\pm$  SD GA  
330 was  $9.59 \pm 3.17$  weeks. The prevalence of self-reported diabetes and oedema was 0% at  
331 inclusion. Moreover, the mean  $\pm$  SD for systolic blood pressure in intervention and control  
332 groups were:  $114 \pm 3$  and  $113 \pm 14$  mmHg, respectively. On the other hand, diastolic blood  
333 pressure was  $69 \pm 9$  mmHg for both trial arms. In our sub-study, the mean  $\pm$  SD duration

334 under supplementation was  $28 \pm 3$  and  $29 \pm 3$  weeks for intervention and control groups,  
335 respectively. Furthermore, the median (IQR) adherence to MMN-fortified BEP was 96% (78,  
336 99) in the intervention group, while mean IFA compliance was >95% in both prenatal study  
337 arms.

338 In the present study, the medians (IQRs) of T/S ratios were 1.00 (0.90, 1.12) in the control  
339 group and 1.00 (0.89, 1.11) in the intervention group, while M/S ratios were 1.11 (0.82, 1.31)  
340 and 1.00 (0.71, 1.33), respectively (**Figure 2**). Our unadjusted complete cases analyses of a  
341 combined daily MMN-fortified BEP supplement and IFA tablet indicated a non-significant  
342 difference in newborn T/S [-0.006 (95% CI: -0.052, 0.040);  $P = 0.810$ ] or M/S ratios [-0.059  
343 (95% CI: -0.196, 0.079);  $P = 0.403$ ], as compared to an IFA tablet alone (**Table 2**). These  
344 findings were confirmed by adjusting the regression models for potential prognostic factors of  
345 study outcomes at enrollment (**Table 2**) and further adjustment for the age of the household  
346 head at inclusion and time between umbilical cord blood collection and storage in the liquid  
347 nitrogen vessel (data not shown).

348 Furthermore, prenatal MMN-fortified BEP and IFA supplementation had an inconsistent  
349 effect on T/S ratio across the percentiles of the newborn TL distribution (**Figure 3**), while a  
350 stronger negative effect on M/S ratio was observed between the ~20<sup>th</sup> and ~60<sup>th</sup> percentile of  
351 the mtDNAC distribution (**Figure 4**). Moreover, (un)adjusted stratified analyses did not  
352 indicate an effective modification of the MMN-fortified BEP intervention on newborn TLs or  
353 mtDNAC by child sex ( $P_{\text{intervention} \times \text{sex}} > 0.10$ ) (**Supplemental Table 3**). Lastly, descriptive  
354 analyses indicated higher, but non-significantly different M/S ratios among children born  
355 either SGA, LBW, or preterm (**Supplemental Table 4**).

356 **Discussion**

357 In the MISAME-III trials, we found that newborns from mothers who received a daily MMN-  
358 fortified BEP supplement and IFA tablet did not have different relative TL or mtDNAc, as  
359 compared to the newborns of females who received an IFA tablet only. Nonetheless, offspring  
360 with adverse birth phenotypes (e.g., SGA, LBW) tended to have higher mtDNAc, likely  
361 indicating mitochondrial dysfunction.

362 Folate is a methyl donor and is a necessary precursor for fetal nucleotide synthesis and cell  
363 proliferation (61). However, in our trial, both the intervention and control groups received  
364 folate, so it is possible that IFA tablets alone had a saturated effect on TL that we were unable  
365 to observe due to the active control arm. Indeed, findings from a previous MISAME-III sub-  
366 study indicated that the nutrient requirements for folate were covered for all pregnant women  
367 (38). Nonetheless, it could be postulated that the vitamin B12 in BEP supplements might have  
368 reduced the amount of folate metabolically trapped as 5-methyltetrahydrofolate (62). The  
369 absence of an increase in TL at birth is in contrast with two prospective cohort studies, based  
370 in the United States of America and South Korea, indicating that higher maternal serum folate  
371 (61) and vitamin D concentrations during pregnancy are associated with longer TL in  
372 newborns (63). Moreover, vitamin D in the BEP upregulates telomerase activity, an essential  
373 enzyme for maintaining TL, while also promoting the expression of Klotho, a protein  
374 associated with longer TLs (64). Pregnancy is a state of low grade chronic inflammation, with  
375 the latter being associated with shorter TL (65). Poly-unsaturated fatty acids (e.g.,  $\omega$ -3)  
376 facilitate anti-inflammatory response, which was therefore hypothesized to lead to longer TL  
377 (23); nonetheless our null findings are consistent with a previous study that indicated prenatal  
378  $\omega$ -3 supplementation did not increase TL in Australia (25). The iron in the MMN-fortified  
379 BEP supplement, in combination with IFA, might have acted as a pro-oxidant (e.g., hydroxyl  
380 free radicals) and mitigated the anti-oxidant effects of other micronutrients (e.g., vitamin C

381 and E) on TL (66). Similar to the current findings of prenatal macronutrient supplementation  
382 in MISAME-III (i.e., 393 kcal with <25% energy from protein), two prospective cohorts, in  
383 South Korea and the United States of America, did not find consistent associations between  
384 higher maternal protein, carbohydrate or fat intakes and their newborn's TL (63,67).

385 The lack of impact of prenatal MMN-fortified BEP supplementation on newborn mtDNAc  
386 compare to findings in Cambodia, where daily iron supplementation (60 mg/day) led to a  
387 decrease in mtDNAc ,but no changes in TL, after 12 weeks among non-pregnant females, as  
388 compared to placebo (68). Similarly, in Indonesia, prenatal MMN supplementation led to a  
389 lower maternal mtDNA copy number, as compared to IFA (29). Our MMN-fortified BEP  
390 supplement contained a plethora of vitamins (e.g., thiamin) and minerals, such as copper,  
391 iodine, selenium, and zinc, which was hypothesized to reduce oxidative stress, protect against  
392 mitochondrial damage and improve mitochondrial stability (69). Moreover, riboflavin is a key  
393 building block in mitochondrial complex I and II (70). The heterogeneity in study results  
394 might be explained by the dynamic nature of mitochondrial homeostasis, in which oxidative  
395 stress-induced damage to mtDNA (e.g., due to iron deficiency or overload) can lead to either  
396 mitochondrial biogenesis or mitophagy, and subsequently increased or decreased mtDNAc  
397 (71). This mitochondrial morphology adjustment is required to prevent metabolic insults, and  
398 consequently alters mitochondrial function to meet cellular energy and metabolic demands  
399 (72). Yet, findings from two American observational studies which indicated that higher  
400 adherence to healthy dietary patterns (73) and higher fruit and vegetables consumption (i.e.,  
401 sources of antioxidants, such as vitamin C and E) are associated with greater mtDNA copy-  
402 numbers in adults (74).

403 In MISAME-III, we observed non-significant differences in newborn TL and mtDNAc across  
404 small samples of birth phenotypes (e.g., SGA vs non-SGA). Similarly, a meta-analysis did not  
405 find that intrauterine growth restriction was associated with shorter TL when measured in

406 cord blood (75). In India, placental mtDNA copy number was significantly greater among  
407 SGA newborns (76), whereas umbilical cord blood mtDNAc was also significantly higher  
408 among growth restricted offspring and mothers who suffered preeclampsia in Italy (77). In  
409 parallel, higher maternal mtDNA copy number was associated with lower birth weights in  
410 Indonesia (18). Conversely, mtDNAc was lower in SGA and large-for-gestational age  
411 Argentinian newborns (3). However, fetal growth faltering was associated with shorter  
412 newborn TL when measured in placental tissue, while TL at birth was significantly longer in  
413 preterm birth than in full-term infants when measured by qPCR (75).

414 Our experimental study has several strengths. Compliance to BEP and IFA supplementation  
415 was verified by a community-based network of home visitors, resulting in high levels of  
416 observed adherence. Furthermore, quantitative 24-hour recalls confirmed that daily energy  
417 and micronutrients requirements were covered by consuming the MMN-fortified BEP  
418 supplement in combination with the usual diet and also ruled out any dietary substitution  
419 effects related to BEP supplementation (38). Moreover, considering that the umbilical cord  
420 blood collection procedure set up was delayed in the study, causing some pregnancies to be  
421 missed, and the remoteness of the study areas, where some participants gave birth outside of  
422 the health center or after working hours, there was still a high collection rate of samples. In  
423 addition, using qPCR, only small amounts of DNA were required (78); therefore, the assay  
424 was simple, rapid, and we were able to achieve a high throughput of the samples (53). Lastly,  
425 although there are alternative methods of telomere measurement, such as telomere restriction  
426 fragment and fluorescent in situ hybridization (FLOW-FISH), these techniques have  
427 limitations in population-based studies. Telomere restriction fragment requires large amounts  
428 of DNA; therefore, it is unsuitable for research with limited quantities of specimens.  
429 Likewise, FLOW-FISH requires fresh blood and so it is not applicable for samples stored at -  
430 80°C (79).

431 Nonetheless, our study had some limitations that warrant caution. First, we did not assess  
432 females' state of inflammation (e.g., C-reactive protein, fibrinogen, interleukin-6, tumor  
433 necrosis factor-alpha), stress (e.g., cortisol), or exposure to environmental contaminants (e.g.,  
434 mycotoxins, black carbon) at inclusion, nor collect information on maternal physical activity  
435 and paternal age at enrolment, hence the use of the household head's age as a proxy variable.  
436 Second, TL and mtDNAc were analyzed at birth only. Therefore, we are unable to evaluate  
437 the effect of MMN-fortified BEP supplementation on infants TL attrition and long-term  
438 changes in mitochondrial functioning. Third, due to limited sample volumes collected from  
439 the umbilical cord we were unable to obtain buffy coat from whole umbilical cord blood. We  
440 acknowledge that analyses on buffy coat have lower bio-variability and higher DNA yields  
441 (79). Fourth, although TL (80) and mtDNAc is known to be heterogeneous across blood cell  
442 types (81), we were unable to assess blood cell counts (e.g., peripheral blood mononuclear  
443 cells, hematopoietic cells, thrombocytes, lymphocytes, neutrophils). Thus, we are unable to  
444 eliminate differential blood compositions between prenatal control and intervention arms.  
445 Fifth, qPCR leads to an estimate of an individual's relative TL, rather than the absolute  
446 number of base pairs (79), which limits the comparability of our findings to other RCTs to the  
447 directions of effects. Sixth, our qPCR assay fails to distinguish functional from dysfunctional  
448 mitochondria, as well as mtDNA retained within intact organelles, rather than mtDNA that  
449 may have leaked into cytoplasm due to nutrient-stress induced damage (82). Lastly, the  
450 average TL does not provide insights into telomere integrity, dysfunctionality, or the amount  
451 of short or critically short telomeres, which might relate to specific telomere pathologies and  
452 diseases (83). In conclusion, our results do not indicate that the provision of daily MMN-  
453 fortified BEP supplements to pregnant females affects newborn TL or mtDNAc. Future  
454 randomized interventions should assess the effects of preconception (84) and prenatal  
455 nutritional supplementation on absolute TLs and more granular measures of mitochondrial



456 bio-energetic functioning (e.g., oxygen consumption rate, mtDNA mutations and deletions),  
457 while larger observational studies might further explore the TLs and mtDNAc of infants born  
458 with adverse phenotypes.

459 **Ethics**

460 The study protocol was approved by the ethics committee of Ghent University Hospital in  
461 Belgium (B670201734334) and the ethics committee of Institut de Recherche en Sciences de  
462 la Santé (50-2020/CEIRES). An independent Data and Safety Monitoring Board (DSMB),  
463 comprising an endocrinologist, two pediatricians, a gynecologist, and an ethicist of both  
464 Belgian and Burkinabe nationalities, was established prior to the start of the efficacy trial. The  
465 DSMB managed remote safety reviews for adverse and serious events at nine and 20 months  
466 after the start of enrolment. The MISAME-III trial was registered on *ClinicalTrials.gov*  
467 (identifier: NCT03533712).

468 **Funding**

469 The MICronutriments pour la SAnté de la Mère et de l'Enfant III (MISAME-III) efficacy trial  
470 was supported by the Bill & Melinda Gates Foundation (Grant number: OPP1175213). The  
471 funder had no role in study design, data collection and analysis, decision to publish, or  
472 preparation of the manuscript. The telomere length and mitochondrial DNA analysis was  
473 supported by the Research Foundation Flanders (Grant numbers: 12X9620N and 12X9623N)  
474 and the European Research Council (ERC) under the European Union's Horizon 2020  
475 research and innovation program (Grant number: 946192, HUMYCO).

476 **Data availability**

477 The informed consent form does not allow sharing of personal data outside the research team.  
478 Requests to access data must be directed to the ethics committee of Ghent University Hospital  
479 through [ethisch.comite@uzgent.be](mailto:ethisch.comite@uzgent.be). Supporting study documents, including the study protocol  
480 and questionnaires, are publicly available on the study's website: <https://misame3.ugent.be>.

481 **Competing interests**

482 The authors have declared that no competing interests exist.

483 **Acknowledgements**

484 The authors thank all the females from Boni, Dohoun, Karaba, Dougoumato II, Koumbia and  
485 Kari who participated in the study and the data collection team. We thank Nutriset (France)  
486 for donating the BEP supplements. The authors' responsibilities were as follows—PK, CL,  
487 LH, LCT, TD-C, GH-C, YBM, MDB and SDS: designed the study; TD-C, YBM, LCT, and  
488 LO: conducted the research; GH-C: analyzed data and performed statistical analysis; DM,  
489 YBM, and TN conducted laboratory analyses; GH-C: developed the first draft and revised the  
490 manuscript; YBM, DM, TD-C, LT, BdK, LO, AA, KT, PK, LH, TN, SDS, MDB, and CL:  
491 critically reviewed the manuscript; and all authors: read and approved the final manuscript.

## References

1. Keats EC, Das JK, Salam RA, Lassi ZS, Imdad A, Black RE, et al. Effective interventions to address maternal and child malnutrition: an update of the evidence. *Lancet Child Adolesc Health*. 2021;5(5):367–84.
2. Entringer S, de Punder K, Buss C, Wadhwa PD. The fetal programming of telomere biology hypothesis: an update. *Philos Trans R Soc Lond B Biol Sci*. 2018 Mar;373(1741):20170151.
3. Gemma C, Sookoian S, Alvariñas J, García SI, Quintana L, Kanevsky D, et al. Mitochondrial DNA depletion in small- and large-for-gestational-age newborns. *Obesity*. 2006;14(12):2193–9.
4. Schulz LC. The Dutch hunger winter and the developmental origins of health and disease. *Proc Natl Acad Sci U S A*. 2010;107(39):16757–8.
5. Gluckman PD, Hanson MA, Buklijas T. A conceptual framework for the developmental origins of health and disease. *J Dev Orig Health Dis*. 2010;1(1):6–18.
6. Prentice AM, Hennig BJ, Fulford AJ. Evolutionary origins of the obesity epidemic: Natural selection of thrifty genes or genetic drift following predation release? *Int J Obes*. 2008;32(11):1607–1610.
7. Speakman JR. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: The “drifty gene” hypothesis. *Int J Obes*. 2008;32(11):1611–1617.
8. Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. *Pediatr Res*. 2007;61(5):31–6.
9. Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science*. 2015;350(6265):1193–8.
10. Wang C, Nawrot TS, Stukken C Van Der, Tylus D, Sleurs H, Peusens M, et al. Different epigenetic signatures of newborn telomere length and telomere attrition rate in early life. *Aging* [Internet]. 2021 Jun 15 [cited 2022 Jul 5];13(11):14630–50. Available from: <https://pubmed.ncbi.nlm.nih.gov/34086604/>
11. Martens DS, Van Der Stukken C, Derom C, Thiery E, Bijmens EM, Nawrot TS. Newborn telomere length predicts later life telomere length: Tracking telomere length from birth to child- and adulthood. *EBioMedicine*. 2021;63:103164.
12. Wang Q, Zhan Y, Pedersen NL, Fang F, Hägg S. Telomere Length and All-Cause Mortality: A Meta-analysis. *Ageing Res Rev*. 2018 Dec;48:11–20.
13. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere length and risk of cardiovascular disease: Systematic review and meta-analysis. *BMJ* (Online). 2014;349:g4227.

14. Zhao J, Miao K, Wang H, Ding H, Wang DW. Association between telomere length and type 2 diabetes mellitus: A meta-analysis. *PLoS One*. 2013;8(11):e79993.
15. Roger AJ, Muñoz-Gómez SA, Kamikawa R. The Origin and Diversification of Mitochondria. *Current Biology*. 2017;27(21):R1177–92.
16. Lee HC, Wei YH. Mitochondrial Role in Life and Death of the Cell. *J Biomed Sci*. 2000;7(1):2–15.
17. Copeland WC, Longley MJ. Mitochondrial genome maintenance in health and disease. *DNA Repair (Amst)* [Internet]. 2014 [cited 2022 Jul 4];19:190–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/24780559/>
18. Priliani L, Febinia CA, Kamal B, Shankar AH, Malik SG. Increased mitochondrial DNA copy number in maternal peripheral blood is associated with low birth weight in Lombok, Indonesia. *Placenta*. 2018 Oct;70:1–3.
19. Lattuada D, Colleoni F, Martinelli A, Garretto A, Magni R, Radaelli T, et al. Higher mitochondrial DNA content in human IUGR placenta. *Placenta*. 2008 Dec;29(12):1029–33.
20. Gibson K, Halliday JL, Kirby DM, Yapfite-Lee J, Thorburn DR, Boneh A. Mitochondrial oxidative phosphorylation disorders presenting in neonates: Clinical manifestations and enzymatic and molecular diagnoses. *Pediatrics*. 2008;122(5):1003–8.
21. Kohda M, Tokuzawa Y, Kishita Y, Nyuzuki H, Moriyama Y, Mizuno Y, et al. A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. *PLoS Genet*. 2016;12(1):e1005679.
22. Druzhyna NM, Wilson GL, LeDoux SP. Mitochondrial DNA repair in aging and disease. *Mech Ageing Dev*. 2008;129(7–8):383–90.
23. Oaks BM, Adu-Afarwuah S, Kumordzie S, Laudenslager ML, Smith DL, Lin J, et al. Impact of a nutritional supplement during gestation and early childhood on child salivary cortisol, hair cortisol, and telomere length at 4–6 years of age: a follow-up of a randomized controlled trial. *Stress*. 2020;23(5):597–606.
24. Lin A, Arnold BF, Mertens AN, Lin J, Benjamin-Chung J, Ali S, et al. Effects of water, sanitation, handwashing, and nutritional interventions on telomere length among children in a cluster-randomized controlled trial in rural Bangladesh. *Elife*. 2017;6:e29365.
25. See VHL, Mas E, Burrows S, O’Callaghan NJ, Fenech M, Prescott SL, et al. Prenatal omega-3 fatty acid supplementation does not affect offspring telomere length and F2-isoprostanes at 12 years: A double blind, randomized controlled trial. *Prostaglandins Leukot Essent Fatty Acids*. 2016;112:50–5.
26. García-Calzón S, Martínez-González MA, Razquin C, Arós F, Lapetra J, Martínez JA, et al. Mediterranean diet and telomere length in high cardiovascular risk subjects from the PREDIMED-NAVARRA study. *Clinical Nutrition*. 2016;35(6):1399–405.

27. Ward SJ, Hill AM, Buckley JD, Banks S, Dhillon VS, Holman SL, et al. Minimal changes in telomere length after a 12-week dietary intervention with almonds in mid-age to older, overweight and obese Australians: Results of a randomised clinical trial. *British Journal of Nutrition*. 2022;127(6):872–84.
28. Tsoukalas D, Fragkiadaki P, Docea AO, Alegakis AK, Sarandi E, Vakonaki E, et al. Association of nutraceutical supplements with longer telomere length. *Int J Mol Med*. 2019;44(1):218–26.
29. Priliani L, Prado EL, Restuadi R, Waturangi DE, Shankar AH, Malik SG. Maternal Multiple Micronutrient Supplementation Stabilizes Mitochondrial DNA Copy Number in Pregnant Women in Lombok, Indonesia. *J Nutr*. 2019 Aug;149(8):1309–16.
30. Vanslambrouck K, De Kok B, Toe LC, De Cock N, Ouedraogo M, Dailey-Chwalibóg T, et al. Effect of balanced energy-protein supplementation during pregnancy and lactation on birth outcomes and infant growth in rural Burkina Faso: Study protocol for a randomised controlled trial. *BMJ Open*. 2021;11(3):1–10.
31. de Kok B, Toe LC, Hanley-Cook G, Argaw A, Ouédraogo M, Compaoré A, et al. Prenatal fortified balanced energy-protein supplementation and birth outcomes in rural Burkina Faso: a randomised controlled efficacy trial. *PLoS Med*. 2022;19(5):e1004002.
32. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *BMJ (Online)*. 2010;340(7748):c332.
33. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. *Clin Chem*. 2009;55(4):611–22.
34. Roberfroid D, Huybregts L, Lanou H, Henry MC, Meda N, Menten J, et al. Effects of maternal multiple micronutrient supplementation on fetal growth: A double-blind randomized controlled trial in rural Burkina Faso. *American Journal of Clinical Nutrition*. 2008;88(5):1330–40.
35. Huybregts L, Roberfroid D, Lanou H, Menten J, Meda N, Van Camp J, et al. Prenatal food supplementation fortified with multiple micronutrients increases birth length: A randomized controlled trial in rural Burkina Faso. *American Journal of Clinical Nutrition*. 2009;90(6):1593–600.
36. Hanley-Cook G, Argaw A, de Kok B, Toe LC, Dailey-Chwalibóg T, Ouédraogo M, et al. Seasonality and Day-to-Day Variability of Dietary Diversity: Longitudinal Study of Pregnant Women Enrolled in a Randomized Controlled Efficacy Trial in Rural Burkina Faso. *Journal of Nutrition*. 2022;152(9):2145–54.
37. Huybregts L, Roberfroid D, Kolsteren P, Van Camp J. Dietary behaviour, food and nutrient intake of pregnant women in a rural community in Burkina Faso. *Matern Child Nutr*. 2009;5(3):211–22.


38. de Kok B, Argaw A, Hanley-Cook G, Toe LC, Ouédraogo M, Dailey-Chwalibóg T, et al. Fortified Balanced Energy-Protein Supplements Increase Nutrient Adequacy without Displacing Food Intake in Pregnant Women in Rural Burkina Faso. *J Nutr.* 2021;151(12):3831–40.
39. de Kok B, Argaw A, Hanley-Cook G, Toe LC, Ouédraogo M, Dailey-Chwalibóg T, et al. Fortified Balanced Energy-Protein Supplements Increase Nutrient Adequacy without Displacing Food Intake in Pregnant Women in Rural Burkina Faso. *J Nutr.* 2021;151(12):3831–40.
40. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *The Lancet.* 2014 Sep;384(9946):857–68.
41. Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: The intention to treat principle and excluding patients from analysis. *BMJ.* 2002;325(7365):652–4.
42. Bill & Melinda Gates Foundation. Framework and specifications for the nutritional composition of a food supplement for pregnant and lactating women (PLW) in undernourished and low income settings. *Gates Open Research.* 2017.
43. Jones L, de Kok B, Moore K, de Pee S, Bedford J, Vanslambrouck K, et al. Acceptability of 12 fortified balanced energy protein supplements - Insights from Burkina Faso. *Matern Child Nutr.* 2021;17(1):1–11.
44. de Kok B, Moore K, Jones L, Vanslambrouck K, Toe LC, Ouédraogo M, et al. Home consumption of two fortified balanced energy protein supplements by pregnant women in Burkina Faso. *Matern Child Nutr.* 2021;17(3):1–13.
45. Food and Nutrition Board, Institute of Medicine, National Academies. *Dietary Reference Intakes (DRIs): Estimated Average Requirements.* 2011.
46. Allen LH, Carriquiry AL, Murphy SP. Perspective: Proposed Harmonized Nutrient Reference Values for Populations. *Advances in Nutrition.* 2020;11(3):469–83.
47. WHO Multicentre Growth Reference Study Group, De Onis M. Reliability of anthropometric measurements in the WHO Multicentre Growth Reference Study. *Acta Paediatr.* 2006;95(S450):38–46.
48. Bastos-Moreira Y, Ouédraogo L, Boevre M De, Argaw A, Kok B de, Hanley-Cook GT, et al. A Multi-Omics and Human Biomonitoring Approach to Assessing the Effectiveness of Fortified Balanced Energy–Protein Supplementation on Maternal and Newborn Health in Burkina Faso: A Study Protocol. *Nutrients* 2023, Vol 15, Page 4056 [Internet]. 2023 Sep 19 [cited 2023 Sep 19];15(18):4056. Available from: <https://www.mdpi.com/2072-6643/15/18/4056/htm>




49. Valadez JJ, Brown LD, Vargas WV, Morley D. Using lot quality assurance sampling to assess measurements for growth monitoring in a developing country's primary health care system. *Int J Epidemiol*. 1996;25(2):381–7.
50. Martens DS, Plusquin M, Gyselaers W, De Vivo I, Nawrot TS. Maternal pre-pregnancy body mass index and newborn telomere length. *BMC Med*. 2016 Oct;14(1):148.
51. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. *Nucleic Acids Res [Internet]*. 2009 Feb 1 [cited 2021 Dec 7];37(3):e21–e21. Available from: <https://academic.oup.com/nar/article/37/3/e21/1074965>
52. Janssen BG, Munters E, Pieters N, Smeets K, Cox B, Cuypers A, et al. Placental mitochondrial DNA content and particulate air pollution during in utero life. *Environ Health Perspect [Internet]*. 2012 [cited 2022 Aug 19];120(9):1346–52. Available from: <http://dx.doi.org/10.1289/ehp.1104458>
53. Cawthon RM. Telomere measurement by quantitative PCR. *Nucleic Acids Res [Internet]*. 2002 May 5 [cited 2022 Aug 5];30(10):e47. Available from: [/pmc/articles/PMC115301/](https://pubmed.ncbi.nlm.nih.gov/115301/)
54. Martens DS, Janssen BG, Bijnens EM, Clemente DBP, Vineis P, Plusquin M, et al. Association of Parental Socioeconomic Status and Newborn Telomere Length. *JAMA Netw Open [Internet]*. 2020 May 1 [cited 2023 Jul 8];3(5):e204057–e204057. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765374>
55. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. *Genome Biol [Internet]*. 2008 Feb 9 [cited 2023 Jul 8];8(2):1–14. Available from: <https://genomebiology.biomedcentral.com/articles/10.1186/gb-2007-8-2-r19>
56. Study Design & Analysis - Telomere Research Network [Internet]. [cited 2023 Jul 8]. Available from: <https://trn.tulane.edu/resources/study-design-analysis/>
57. Hanley-Cook GT, Toe LC, Tesfamariam K, de Kok B, Argaw A, Compaoré A, et al. Fortified Balanced Energy-Protein Supplementation, Maternal Anemia, and Gestational Weight Gain: a Randomized Controlled Efficacy Trial Among Pregnant Women in Rural Burkina Faso. *Journal of Nutrition*. 2022;152(10):2277–86.
58. Unryn BM, Cook LS, Riabowol KT. Paternal age is positively linked to telomere length of children. *Aging Cell*. 2005;4(2):97–101.
59. Katz J, Christian P, Dominici F, Zeger SL. Treatment effects of maternal micronutrient supplementation vary by percentiles of the birth weight distribution in rural Nepal. *Journal of Nutrition*. 2006;136(5):1389–94.
60. Roberfroid D, Huybregts L, Lanou H, Henry MC, Meda N, Menten J, et al. Effects of maternal multiple micronutrient supplementation on fetal growth: A double-blind randomized controlled trial in rural Burkina Faso. *American Journal of Clinical Nutrition*. 2008;88(5):1330–40.

61. Entringer S, Epel ES, Lin J, Blackburn EH, Buss C, Shahbaba B, et al. Maternal Folate Concentration in Early Pregnancy and Newborn Telomere Length. *Ann Nutr Metab*. 2015;66(4):202–8.
62. Shane B, Stokstad EL. Vitamin B12-folate interrelationships. *Annu Rev Nutr*. 1985;5:115–41.
63. Kim JH, Kim GJ, Lee D, Ko JH, Lim I, Bang H, et al. Higher maternal vitamin D concentrations are associated with longer leukocyte telomeres in newborns. *Matern Child Nutr*. 2018;14(1):e12475.
64. Ullah M, Sun Z, Hare JM. Klotho Deficiency Accelerates Stem Cells Aging by Impairing Telomerase Activity. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*. 2019;74(9):1396–407.
65. O'Donovan A, Pantell MS, Puterman E, Dhabhar FS, Blackburn EH, Yaffe K, et al. Cumulative inflammatory load is associated with short leukocyte telomere length in the health, aging and body composition study. *PLoS One*. 2011;6(5):e19687.
66. Xu Q, Parks CG, Deroo LA, Cawthon RM, Sandler DP, Chen H. Multivitamin use and telomere length in women 1-3. *Am J Clin Nutr*. 2009;89(6):1857–63.
67. Salihu HM, Adegoke KK, King LM, Daas R, Paothong A, Pradhan A, et al. Effects of Maternal Carbohydrate and Fat Intake on Fetal Telomere Length. *South Med J*. 2018;111(10):591–6.
68. Steele SL, Hsieh AYY, Gadawski I, Kroeun H, Barr SI, Devlin AM, et al. Daily oral supplementation with 60 mg of elemental iron for 12 weeks alters blood mitochondrial dna content, but not leukocyte telomere length in cambodian women. *Nutrients*. 2021;13(6):1877.
69. Yang X, Zhang R, Nakahira K, Gu Z. Mitochondrial DNA Mutation, Diseases, and Nutrient-Regulated Mitophagy. *Annu Rev Nutr*. 2019;39:201–26.
70. Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R. A modern approach to the treatment of mitochondrial disease. *Curr Treat Options Neurol*. 2009;11(6):414–30.
71. Palikaras K, Tavernarakis N. Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis. *Exp Gerontol*. 2014;56:182–8.
72. Eisner V, Picard M, Hajnóczky G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. *Nat Cell Biol*. 2018;20(7):755–765.
73. Ma J, Liu X, Zhang Y, Cheng H, Gao W, Lai CQ, et al. Diet Quality Scores Are Positively Associated with Whole Blood-Derived Mitochondrial DNA Copy Number in the Framingham Heart Study. *Journal of Nutrition*. 2022;152(3):690–7.
74. Wu S, Li X, Meng S, Fung T, Chan AT, Liang G, et al. Fruit and vegetable consumption, cigarette smoke, and leukocyte mitochondrial DNA copy number. *American Journal of Clinical Nutrition*. 2019;109(2):424–32.
75. Niu Z, Li K, Xie C, Wen X. Adverse Birth Outcomes and Birth Telomere Length: A Systematic Review and Meta-Analysis. *Journal of Pediatrics*. 2019;215:201–26.


76. Naha R, Anees A, Chakrabarty S, Naik PS, Pandove M, Pandey D, et al. Placental mitochondrial DNA mutations and copy numbers in intrauterine growth restricted (IUGR) pregnancy. *Mitochondrion*. 2020;55:85–94.
77. Novielli C, Mandò C, Tabano S, Anelli GM, Fontana L, Antonazzo P, et al. Mitochondrial DNA content and methylation in fetal cord blood of pregnancies with placental insufficiency. *Placenta*. 2017 Jul;55:63–70.
78. Montpetit AJ, Alhareeri AA, Montpetit M, Starkweather AR, Elmore LW, Filler K, et al. Telomere length: a review of methods for measurement. *Nurs Res*. 2014;63(4):289–99.
79. Lin J, Smith DL, Esteves K, Drury S. Telomere length measurement by qPCR – Summary of critical factors and recommendations for assay design. Vol. 99, *Psychoneuroendocrinology*. 2019. p. 271–8.
80. Lin J, Cheon J, Brown R, Coccia M, Puterman E, Aschbacher K, et al. Systematic and Cell Type-Specific Telomere Length Changes in Subsets of Lymphocytes. *J Immunol Res*. 2016;2016:5371050.
81. Knez J, Winckelmans E, Plusquin M, Thijs L, Cauwenberghs N, Gu Y, et al. Correlates of Peripheral Blood Mitochondrial DNA Content in a General Population. *Am J Epidemiol*. 2016;183(2):138–46.
82. Chou YF, Huang RFS. Mitochondrial DNA deletions of blood lymphocytes as genetic markers of low folate-related mitochondrial genotoxicity in peripheral tissues. *Eur J Nutr*. 2009;48(7):429–36.
83. Garcia-Martin I, Janssen AB, Jones RE, Grimstead JW, Penketh RJA, Baird DM, et al. Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis. *Placenta*. 2017 Nov;59:61–8.
84. Maasen K, James PT, Prentice AM, Moore SE, Fall CH, Chandak GR, et al. Periconceptional environment predicts leukocyte telomere length in a cross-sectional study of 7-9 year old rural Gambian children. *Sci Rep*. 2020;10(1):9675.
85. Coates J, Swindale A, Bilinsky P. Household Food Insecurity Access Scale (HFIAS) for Measurement of Food Access: Indicator Guide (v.3). Washington, D.C.: Food and Nutrition Technical Assistance Project & FHI 360; 2007. 29 p.




**Figure 1. MISAME-III trial flow chart.** DNA, deoxyribonucleic acid; T/S, telomere copy number to a single-copy gene number; MISAME-III, Micronutriments pour la Santé de la Mère et de l'Enfant study 3; M/S, mitochondrial gene copy number to a single-copy gene number.



**Figure 2. Box and whisker plots of newborn telomere length (left) and mitochondrial DNA content (right), by MISAME-III trial arm.** T/S, telomere copy number to a single-copy gene number; MISAME-III, Micronutriments pour la Santé de la Mère et de l'Enfant study 3; M/S, mitochondrial gene copy number to a single-copy gene number.



**Figure 3. Treatment efficacy on T/S ratio across the distribution of T/S ratio.** The estimated difference in T/S ratio between the women who received the MMN-fortified BEP supplement and IFA (intervention) and those who received only iron and folic acid (control) is shown as a function of the percentiles of T/S ratio. The zero line indicates no efficacy of the multiple micronutrient-fortified BEP. The positive y values indicate a higher T/S ratio in the intervention group, and the negative y values indicate a lower T/S ratio. The central solid black line represents the smoothed treatment efficacy, with upper and lower dashed 95% confidence bands, using complete cases. BEP, balanced energy-protein; IFA, iron-folic acid; MMN, multiple micronutrients; T/S, telomere copy number to a single-copy gene number.



**Figure 4. Treatment efficacy on M/S ratio across the distribution of M/S ratio.** The estimated difference in M/S ratio between the women who received the MMN -fortified BEP supplement and IFA (intervention) and those who received only iron and folic acid (control) is shown as a function of the percentiles of M/S ratio. The zero line indicates no efficacy of BEP. The positive y values indicate a higher M/S ratio in the intervention group, and the negative y values indicate a lower M/S ratio. The central solid black line represents the smoothed treatment efficacy, with upper and lower dashed 95% confidence bands, using complete cases. BEP, balanced energy-protein; IFA, iron-folic acid; MMN, multiple micronutrients; M/S, mitochondrial gene copy number to a single-copy gene number.

**Table 1. Baseline characteristics of study participants, by MISAME-III trial arm<sup>1</sup>**

| Characteristics                            | Control (n = 104) | Intervention (n = 90) |
|--|-------------------|-----------------------|
| <b>Health centre catchment area</b>        |                   |                       |
| Boni                                       | 17 (16.3)         | 16 (17.8)             |
| Dohoun                                     | 14 (13.5)         | 13 (14.4)             |
| Dougoumato II                              | 13 (12.5)         | 14 (15.6)             |
| Karaba                                     | 11 (10.6)         | 8 (8.89)              |
| Kari                                       | 21 (20.2)         | 21 (23.3)             |
| Koumbia                                    | 28 (26.9)         | 18 (20.0)             |
| <b>Household level</b>                     |                   |                       |
| Wealth index, 0-10 points                  | 4.32 ± 1.72       | 5.02 ± 1.77           |
| Household food insecurity <sup>2</sup>     | 72 (69.2)         | 64 (71.1)             |
| Improved primary water source <sup>3</sup> | 62 (59.6)         | 52 (57.8)             |
| Improved sanitation facility <sup>4</sup>  | 68 (65.4)         | 54 (60.0)             |
| Household size                             | 5.85 ± 4.34       | 6.89 ± 4.74           |
| Polygamous households                      | 38 (36.5)         | 40 (44.4)             |
| <b>Head of household</b>                   |                   |                       |
| Age, years                                 | 32.3 ± 8.83       | 32.2 ± 9.31           |
| Male                                       | 103 (99.0)        | 90 (100)              |
| Completed primary education                | 63 (60.6)         | 55 (61.1)             |
| <b>Maternal</b>                            |                   |                       |
| Age, years                                 | 24.0 ± 5.47       | 24.0 ± 5.70           |
| <b>Ethnic group</b>                        |                   |                       |
| Bwaba                                      | 57 (54.8)         | 51 (56.7)             |
| Mossi                                      | 36 (34.6)         | 30 (33.3)             |
| Other                                      | 11 (10.6)         | 9 (10.0)              |
| <b>Religion</b>                            |                   |                       |
| Muslim                                     | 47 (45.2)         | 41 (45.6)             |
| Animist                                    | 26 (25.0)         | 22 (24.4)             |
| Protestant                                 | 23 (22.1)         | 19 (21.1)             |
| Catholic                                   | 6 (5.77)          | 6 (6.66)              |
| No religion, no animist                    | 2 (1.92)          | 2 (2.22)              |
| Completed primary education                | 53 (51.0)         | 37 (41.1)             |
| Weight, kg                                 | 58.9 ± 10.7       | 58.1 ± 7.88           |
| Height, cm                                 | 162 ± 5.83        | 163 ± 5.83            |
| BMI, kg/m <sup>2</sup>                     | 22.4 ± 3.54       | 21.9 ± 2.65           |
| <18.5 kg/m <sup>2</sup>                    | 8 (7.69)          | 4 (4.44)              |
| Mid-upper arm circumference, mm            | 263 ± 31.9        | 261 ± 24.0            |
| Subscapular skinfold, mm                   | 12.5 ± 7.18       | 11.8 ± 5.55           |
| Tricipital skinfold, mm                    | 11.9 ± 5.53       | 11.5 ± 4.38           |



|                           |             |             |
|---------------------------|-------------|-------------|
| Haemoglobin (Hb), g/dl    | 11.8 ± 1.34 | 11.8 ± 1.39 |
| Anemia (Hb <11 g/dl)      | 23 (22.1)   | 28 (31.1)   |
| Severe anemia (Hb <7g/dl) | 0 (0)       | 0 (0)       |
| Gestational age, weeks    | 9.43 ± 2.96 | 9.78 ± 3.41 |
| Trimester of gestation    |             |             |
| First                     | 86 (82.7)   | 74 (82.2)   |
| Second                    | 18 (17.3)   | 16 (17.8)   |
| Parity                    |             |             |
| 0                         | 26 (25.0)   | 26 (28.9)   |
| 1-2                       | 49 (47.1)   | 32 (35.6)   |
| ≥3                        | 29 (27.9)   | 32 (35.6)   |

<sup>1</sup>Data are frequencies (%) or means ± standard deviation. BMI, body mass index; Hb, hemoglobin. MISAME-III, Micronutriments pour la Santé de la Mère et de l'Enfant study 3.

<sup>2</sup>Assessed using FANTA/USAID's Household Food Insecurity Access Scale (85). Missing for one female in the control group.

<sup>3</sup>Protected well, borehole, pipe or bottled water were considered improved water sources.

<sup>4</sup>Flush toilet connected to local sewage or septic tank, or pit latrine with slab and/or ventilation were considered improved sanitation facilities.

**Table 2.**  
**Efficacy of prenatal multiple micronutrient-fortified**


| <b>Birth characteristics</b> | <b>Control<sup>1</sup><br/>(n = 104)</b> | <b>Intervention<sup>1</sup><br/>(n = 88)</b> | <b>Unadjusted <math>\Delta^3</math><br/>(95% CI)</b> | <b>P-value</b> | <b>Adjusted <math>\Delta^3</math><br/>(95% CI)</b> | <b>P- value</b> |
|------------------------------|--|--|--|----------------|--|-----------------|
| T/S ratio                    | 1.01 ± 0.154                             | 1.01 ± 0.163                                 | -0.006 (-0.052, 0.040)                               | 0.810          | -0.007 (-0.056, 0.042)                             | 0.773           |
| M/S ratio                    | 1.12 ± 0.438 <sup>2</sup>                | 1.05 ± 0.455                                 | -0.059 (-0.196, 0.079)                               | 0.403          | -0.047 (-0.194, 0.099)                             | 0.523           |

**BEP supplementation on relative telomere and mitochondrial DNA content**


<sup>1</sup>Values are means ± standard deviation. CI, confidence interval; T/S, telomere copy number to a single-copy gene number; M/S, mitochondrial gene copy number to a single-copy gene number,

<sup>2</sup>M/S ratio for 103 women in the control group.

<sup>3</sup>Unadjusted and adjusted group differences ( $\Delta$ ) were estimated by fitting linear regression models. All models contained health center, randomization block, and quantitative polymerase chain reaction plate as fixed effects to account for clustering by the study design. Adjusted models additionally contained a set potential prognostic factors of outcomes including wealth index, maternal age, primiparity, gestational age, height, mid-upper arm circumference, body mass index, and hemoglobin level at study enrolment.



**Supplemental Figure 1. Standardized normal probability (top) and quantile-quantile (bottom) plots of unadjusted regression residuals for T/S ratio. T/S, telomere copy number to a single-copy gene number.**



**Supplemental Figure 2. Standardized normal probability (top) and quantile-quantile (bottom) plots of unadjusted regression residuals for M/S ratio. M/S, mitochondrial gene copy number to a single-copy gene number.**

**Supplemental Table 1. Nutritional values of the ready-to-use supplementary food for pregnant and lactating women<sup>1</sup>**

|   | Mean for 72g (serving size) |
|---|-----------------------------|
| Total energy (kcal)                               | 393                         |
| Lipids (g)  | 26                          |
| Linoleic acid (g)                                 | 3.9                         |
| $\alpha$ -Linoleic acid (g)                       | 1.3                         |
| Proteins (g)                                      | 14.5                        |
| Carbohydrates (g)                                 | 23.3                        |
| Calcium (mg)                                      | 500                         |
| Copper (mg)                                       | 1.3                         |
| Phosphorus (mg)                                   | 418                         |
| Iodine ( $\mu$ g)                                 | 250                         |
| Iron (mg)   | 22                          |
| Selenium ( $\mu$ g)                               | 65                          |
| Manganese (mg)                                    | 2.1                         |
| Magnesium (mg)                                    | 73                          |
| Potassium (mg)                                    | 562                         |
| Zinc (mg)   | 15                          |
| Vitamin A ( $\mu$ g RE) <sup>2</sup>              | 770                         |
| Thiamin (mg)                                      | 1.4                         |
| Riboflavin (mg)                                   | 1.4                         |
| Niacin (mg)                                       | 15                          |
| Vitamin B5 (mg)                                   | 7                           |
| Vitamin B6 (mg)                                   | 1.9                         |
| Folic acid ( $\mu$ g)                             | 400                         |
| Vitamin B12 ( $\mu$ g)                            | 2.6                         |
| Vitamin C (mg)                                    | 100                         |
| Vitamin D ( $\mu$ g cholecalciferol) <sup>3</sup> | 15                          |
| Vitamin E (mg $\alpha$ -tocopherol) <sup>4</sup>  | 18                          |
| Vitamin K ( $\mu$ g)                              | 72                          |

<sup>1</sup>Ingredients: vegetable oils (rapeseed, palm, and soy in varying proportions), defatted soy flour, skimmed milk powder, peanuts, sugar, maltodextrin, soy protein isolate, vitamin and mineral complex, stabilizer (fully hydrogenated vegetable fat, mono-, and diglycerides). IU, international unit, RE, retinol equivalent.

<sup>2</sup>1  $\mu$ g vitamin A RE = 3.333 IU vitamin A.

<sup>3</sup>1  $\mu$ g cholecalciferol = 40 IU vitamin D.

<sup>4</sup>1 mg  $\alpha$ -tocopherol = 2,22 IU vitamin E.

**Supplemental table 2. Differences in baseline characteristics of study participants, by MISAME-III trial arm<sup>1</sup>**

| Characteristics                            | Control (n = 104) | Intervention (n = 90) | P-value <sup>5</sup> |
|--|-------------------|-----------------------|----------------------|
| <b>Health centre catchment area</b>        |                   |                       | 0.88                 |
| Boni                                       | 17 (16.3)         | 16 (17.8)             |                      |
| Dohoun                                     | 14 (13.5)         | 13 (14.4)             |                      |
| Dougoumato II                              | 13 (12.5)         | 14 (15.6)             |                      |
| Karaba                                     | 11 (10.6)         | 8 (8.89)              |                      |
| Kari                                       | 21 (20.2)         | 21 (23.3)             |                      |
| Koumbia                                    | 28 (26.9)         | 18 (20.0)             |                      |
| <b>Household level</b>                     |                   |                       |                      |
| Wealth index, 0-10 points                  | 4.32 ± 1.72       | 5.02 ± 1.77           | 0.006                |
| Household food insecurity <sup>2</sup>     | 72 (69.2)         | 64 (71.1)             | 0.68                 |
| Improved primary water source <sup>3</sup> | 62 (59.6)         | 52 (57.8)             | 0.80                 |
| Improved sanitation facility <sup>4</sup>  | 68 (65.4)         | 54 (60.0)             | 0.44                 |
| Household size                             | 5.85 ± 4.34       | 6.89 ± 4.74           | 0.11                 |
| Polygamous households                      | 38 (36.5)         | 40 (44.4)             | 0.26                 |
| <b>Head of household</b>                   |                   |                       |                      |
| Age, years                                 | 32.3 ± 8.83       | 32.2 ± 9.31           | 0.95                 |
| Male                                       | 103 (99.0)        | 90 (100)              | 0.35                 |
| Completed primary education                | 63 (60.6)         | 55 (61.1)             |                      |
| <b>Maternal</b>                            |                   |                       |                      |
| Age, years                                 | 24.0 ± 5.47       | 24.0 ± 5.70           | 1.00                 |
| Ethnic group                               |                   |                       | 0.59                 |
| Bwaba                                      | 57 (54.8)         | 51 (56.7)             |                      |
| Mossi                                      | 36 (34.6)         | 30 (33.3)             |                      |
| Other                                      | 11 (10.6)         | 9 (10.0)              |                      |
| Religion                                   |                   |                       | 0.92                 |
| Muslim                                     | 47 (45.2)         | 41 (45.6)             |                      |
| Animist                                    | 26 (25.0)         | 22 (24.4)             |                      |
| Protestant                                 | 23 (22.1)         | 19 (21.1)             |                      |
| Catholic                                   | 6 (5.77)          | 6 (6.66)              |                      |
| No religion, no animist                    | 2 (1.92)          | 2 (2.22)              |                      |
| Completed primary education                | 53 (51.0)         | 37 (41.1)             | 0.17                 |
| Weight, kg                                 | 58.9 ± 10.7       | 58.1 ± 7.88           | 0.54                 |
| Height, cm                                 | 162 ± 5.83        | 163 ± 5.83            | 0.36                 |

|                                 |             |             |      |
|---------------------------------|-------------|-------------|------|
| BMI, kg/m <sup>2</sup>          | 22.4 ± 3.54 | 21.9 ± 2.65 | 0.27 |
| <18.5 kg/m <sup>2</sup>         | 8 (7.69)    | 4 (4.44)    | 0.35 |
| Mid-upper arm circumference, mm | 263 ± 31.9  | 261 ± 24.0  | 0.56 |
| Subscapular skinfold, mm        | 12.5 ± 7.18 | 11.8 ± 5.55 | 0.43 |
| Tricipital skinfold, mm         | 11.9 ± 5.53 | 11.5 ± 4.38 | 0.59 |
| Haemoglobin (Hb), g/dl          | 11.8 ± 1.34 | 11.8 ± 1.39 | 0.83 |
| Anemia (Hb <11g/dl)             | 23 (22.1)   | 28 (31.1)   |      |
| Severe anemia (Hb <7g/dl)       | 0 (0)       | 0 (0)       | 1.00 |
| Gestational age, weeks          | 9.43 ± 2.96 | 9.78 ± 3.41 | 0.45 |
| Trimester of gestation          |             |             | 0.93 |
| First                           | 86 (82.7)   | 74 (82.2)   |      |
| Second                          | 18 (17.3)   | 16 (17.8)   |      |
| Parity                          |             |             | 0.26 |
| 0                               | 26 (25.0)   | 26 (28.9)   |      |
| 1-2                             | 49 (47.1)   | 32 (35.6)   |      |
| ≥3                              | 29 (27.9)   | 32 (35.6)   |      |

<sup>1</sup>Data are frequencies (%) or means ± standard deviation. BMI, body mass index; Hb, hemoglobin. MISAME-III, Micronutriments pour la Santé de la Mère et de l'Enfant study 3.

<sup>2</sup>Assessed using FANTA/USAID's Household Food Insecurity Access Scale (79). Missing for one female in the control group.

<sup>3</sup>Protected well, borehole, pipe or bottled water were considered improved water sources.

<sup>4</sup>Flush toilet connected to local sewage or septic tank, or pit latrine with slab and/or ventilation were considered improved sanitation facilities.

<sup>5</sup>Two-sided t-test for continuous variables and Pearson's chi-squared test for categorical variables.

**Supplemental Table 3. Efficacy of prenatal multiple micronutrients-fortified BEP supplementation on relative telomere length and mitochondrial DNA content, by child sex**

| Birth characteristics | Control <sup>1</sup><br>( <i>n</i> = 104) | Intervention <sup>1</sup><br>( <i>n</i> = 88) | Unadjusted $\Delta^3$<br>(95% CI) | <i>P</i> -value    | Adjusted $\Delta^3$<br>(95% CI) | <i>P</i> - value   |
|-----------------------|---|---|-----------------------------------|--------------------|---------------------------------|--------------------|
| T/S ratio             |   |   |                                   | 0.445 <sup>4</sup> |                                 | 0.414 <sup>4</sup> |
| Female                | 56 (53.8)                                 | 36 (40.9)                                     | -0.025 (-0.100, 0.050)            | 0.506              | -0.038 (-0.125, 0.049)          | 0.385              |
| Male                  | 48 (46.2)                                 | 52 (59.1)                                     | 0.001 (-0.071, 0.068)             | 0.967              | 0.003 (-0.075, 0.080)           | 0.946              |
| M/S ratio             |   |   |                                   | 0.682 <sup>4</sup> |                                 | 0.600 <sup>d</sup> |
| Female                | 55 (53.3) <sup>2</sup>                    | 35 (39.8)                                     | -0.094 (-0.323, 0.134)            | 0.412              | -0.022 (-0.275, 0.230)          | 0.859              |
| Male                  | 48 (46.6) <sup>2</sup>                    | 53 (60.2)                                     | -0.145 (-0.363, 0.073)            | 0.188              | -0.128 (-0.365, 0.109)          | 0.284              |

<sup>1</sup>Values are frequencies (%). CI, confidence interval; T/S, telomere copy number to a single-copy gene number; M/S, mitochondrial gene copy number to a single-copy gene number

<sup>2</sup>M/S ratio for 103 women in the control group.

<sup>3</sup>Unadjusted and adjusted group differences ( $\Delta$ ) were estimated by fitting linear regression models. All models contained health centre, randomization block, and quantitative polymerase chain reaction plate as fixed effects to account for clustering by the study design. Adjusted models additionally contained a set of potential prognostic factors of outcomes including wealth index, maternal age, primiparity, gestational age, height, mid-upper arm circumference, body mass index, and haemoglobin level at study enrolment.

<sup>4</sup>Statistical significance was set at  $P < 0.10$  for interactions.



**Supplemental Table 4. Relative telomere lengths and mitochondrial DNA content, by birth phenotype<sup>1</sup>**

| Birth characteristics | SGA (<10 <sup>th</sup> percentile) <sup>2</sup> |                            | <i>P</i> -value <sup>3</sup> | LBW (<2,500g)              |                            | <i>P</i> -value <sup>3</sup> | Preterm delivery (<37 weeks) |                           | <i>P</i> -value <sup>3</sup> |
|-----------------------|---|----------------------------|------------------------------|----------------------------|----------------------------|------------------------------|------------------------------|---------------------------|------------------------------|
|                       | No ( <i>n</i> = 148)                            | Yes ( <i>n</i> = 44)       |                              | No ( <i>n</i> = 177)       | Yes ( <i>n</i> = 15)       |                              | No ( <i>n</i> = 189)         | Yes ( <i>n</i> = 3)       |                              |
| T/S ratio             | 1.01 ± 0.165                                    | 1.01 ± 0.134               | 0.987                        | 1.01 ± 0.161               | 1.01 ± 0.121               | 0.931                        | 1.01 ± 0.159                 | 0.932 ± 0.101             | 0.367                        |
|                       | <b>No (<i>n</i> = 147)</b>                      | <b>Yes (<i>n</i> = 44)</b> |                              | <b>No (<i>n</i> = 176)</b> | <b>Yes (<i>n</i> = 15)</b> |                              | <b>No (<i>n</i> = 188)</b>   | <b>Yes (<i>n</i> = 3)</b> |                              |
| M/S ratio             | 1.07 ± 0.441                                    | 1.16 ± 0.463               | 0.241                        | 1.08 ± 0.426               | 1.21 ± 0.642               | 0.303                        | 1.09 ± 0.438                 | 1.33 ± 0.942              | 0.349                        |

<sup>1</sup>Values are means ± standard deviation. LBW, low birthweight, SGA, small-for-gestational age; T/S, telomere copy number to a single-copy gene number; M/S, mitochondrial gene copy number to a single-copy gene number.

<sup>2</sup>Defined as the proportion of newborns with a birthweight below the 10<sup>th</sup> percentile of the International Fetal and Newborn Growth Consortium for the 21<sup>st</sup> Century (INTERGROWTH-21st newborn size standards for a given gestational age at delivery (40).

<sup>3</sup>Two-sided Student's *t*-test.

## References

1. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet*. 2014 Sep;384(9946):857–68.



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

| Section/Topic             | Item No | Checklist item  | Reported on page No |
|---------------------------|---------|---|---------------------|
| <b>Title and abstract</b> |         |   |                     |
|                           | 1a      | Identification as a randomised trial in the title   |                     |
|                           | 1b      | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)               |                     |
| <b>Introduction</b>       |         |   |                     |
| Background and objectives | 2a      | Scientific background and explanation of rationale  | 3-5                 |
|                           | 2b      | Specific objectives or hypotheses   | 5                   |
| <b>Methods</b>            |         |   |                     |
| Trial design              | 3a      | Description of trial design (such as parallel, factorial) including allocation ratio  | 6                   |
|                           | 3b      | Important changes to methods after trial commencement (such as eligibility criteria), with reasons                                    |                     |
| Participants              | 4a      | Eligibility criteria for participants   | 7                   |
|                           | 4b      | Settings and locations where the data were collected  | 6                   |
| Interventions             | 5       | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 7                   |
| Outcomes                  | 6a      | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed                    | 5                   |
|                           | 6b      | Any changes to trial outcomes after the trial commenced, with reasons   |                     |
| Sample size               | 7a      | How sample size was determined  | 6-8                 |
|                           | 7b      | When applicable, explanation of any interim analyses and stopping guidelines  |                     |
| Randomisation:            |         |   |                     |

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

|  |     |   |              |
|--|-----|---|--------------|
| Sequence generation  | 8a  | Method used to generate the random allocation sequence  | 7 and 8      |
|  | 8b  | Type of randomisation; details of any restriction (such as blocking and block size)   | 7 and 8      |
| Allocation concealment mechanism                                       | 9   | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 7 and 8      |
|  | 10  | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions   | 7 and 8      |
| Blinding   | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how  | 6-8          |
|  | 11b | If relevant, description of the similarity of interventions   |              |
| Statistical methods  | 12a | Statistical methods used to compare groups for primary and secondary outcomes   | 15 and 16    |
|  | 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses  | 15 and 16    |
| <b>Results</b><br>Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome  | 17           |
|  | 13b | For each group, losses and exclusions after randomisation, together with reasons  | 17           |
| Recruitment  | 14a | Dates defining the periods of recruitment and follow-up   | 17           |
|  | 14b | Why the trial ended or was stopped  | 17 and 18    |
| Baseline data  | 15  | A table showing baseline demographic and clinical characteristics for each group  | 38-39, 44-45 |
| Numbers analysed   | 16  | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups   | 17           |
| Outcomes and estimation  | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)   | 46           |

|                          |     |   |           |
|--------------------------|-----|---|-----------|
|                          | 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended   |           |
| Ancillary analyses       | 18  | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 17 and 18 |
| Harms                    | 19  | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)                                     |           |
| <b>Discussion</b>        |     |   |           |
| Limitations              | 20  | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses                          | 22 and 23 |
| Generalisability         | 21  | Generalisability (external validity, applicability) of the trial findings   | 19-23     |
| Interpretation           | 22  | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence                             | 19-23     |
| <b>Other information</b> |     |   |           |
| Registration             | 23  | Registration number and name of trial registry  | 24        |
| Protocol                 | 24  | Where the full trial protocol can be accessed, if available   | 24        |
| Funding                  | 25  | Sources of funding and other support (such as supply of drugs), role of funders   | 25        |

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).